Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
20 hedge funds and large institutions have $4.24M invested in Amplify Treatments, Testing and Advancements ETF in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
804% more capital invested
Capital invested by funds: $469K → $4.24M (+$3.77M)
433% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 3
186% more funds holding
Funds holding: 7 → 20 (+13)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.39M |
| 2 |
Goldman Sachs
New York
|
+$860K |
| 3 |
Jane Street
New York
|
+$789K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$460K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BSG
Black Swift Group
Boulder,
Colorado
|
-$143K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$11K |
| 3 |
PIMG
Patriot Investment Management Group
Knoxville,
Tennessee
|
-$5.71K |
| 4 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
-$2.65K |
GERM Hedge Fund Activity: Q3 2020 in Review
20 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q3 2020, worth a combined $4.24M — up 804% from $469K a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new GERM positions and 3 closed out — a net gain of 13 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Osaic Holdings, opening a new position worth an estimated $1.39M. The largest seller was Black Swift Group, exiting entirely with an estimated $143K sold.
- 20 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q3 2020, up from 7 in Q2 2020.
- Funds reported $4.24M of Amplify Treatments, Testing and Advancements ETF stock for Q3 2020, up 804% quarter-over-quarter.
- 16 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q3 2020 and 3 closed out, a net change of +13 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q3 2020 was Osaic Holdings, an estimated $1.39M added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q3 2020 was Black Swift Group, an estimated $143K sold.
Based on aggregated 13F filings for Q3 2020.